HIV Vaccine Mandate Closer as FDA approves Long-Acting Injectable Apretude

HIV Vaccine Mandate Closer as FDA approves Long-Acting Injectable Apretude



The Food and Drug Administration (FDA) announced on Monday that it approved Cabotegravir, branded as Apretude, the first long-acting injectable medication for HIV.  The pre-exposure prophylaxis (PrEP) injection is administered every two months after a run-up as a monthly dose for two months.1 

Just prior to its approval, public service announcement style news articles for then Cabotegravir were widely circulated where the Centers for Disease Control (CDC) called for a dramatic expansion in PrEP use for HIV prevention.  In what appears to be an unwitting revelation, the article included an admonishment that healthcare providers now begin to “discuss PrEP with every patient who’s sexually active.”2  Conceivably, this could be a patient population of everyone between the ages of, say, 16 to 80 years old.  This is a very significant change in broadcasting the medication.

Because the virus is primarily spread in marginalized communities, the government currently classifies HIV as an epidemic.  Expanding the affected population base to include all sexual behaviors would be a first step in reclassifying it to a pandemic.  As HIV is an incurable, life threatening virus, the new injectable Apretude could seem to easily classify as a vaccine.  While it may be observed that, unlike traditional vaccines, Apretude must be taken regularly (six times a year), the same can be said for the Coivid-19 ‘vaccine’ as it responds to continued failures. 



  1. FDA Approves First Long-Acting Injectable to Prevent HIV Infection, MedPageToday, December 21, 2021.
  2. “CDC recommends dramatic expansion of HIV prevention medication,” ABC 7, Eyewitness News, Los Angeles [citation #7, emphasis added]. December 8, 2021.
This entry was posted in Covid-19, FDA, HIV, PrEP, Vaccine and tagged , , , , , . Bookmark the permalink.